Shares of Prothena Co. PLC (NASDAQ:PRTA) have received a consensus rating of “Hold” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $34.57.
PRTA has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. BidaskClub downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 13th. Oppenheimer reiterated a “hold” rating on shares of Prothena in a research note on Sunday, November 11th. ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $18.00 target price on shares of Prothena in a research note on Wednesday, August 8th.
Shares of NASDAQ PRTA opened at $11.99 on Friday. The company has a market capitalization of $475.57 million, a PE ratio of -2.95 and a beta of 2.63. Prothena has a 52-week low of $10.43 and a 52-week high of $47.84.
Institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. lifted its position in Prothena by 47.7% during the second quarter. Oppenheimer & Co. Inc. now owns 11,455 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,700 shares during the period. Raymond James & Associates bought a new position in Prothena during the second quarter valued at approximately $170,000. Xact Kapitalforvaltning AB bought a new position in Prothena during the first quarter valued at approximately $210,000. LPL Financial LLC bought a new position in Prothena during the first quarter valued at approximately $210,000. Finally, Senzar Asset Management LLC bought a new position in Prothena during the second quarter valued at approximately $249,000.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Recommended Story: Cost of Debt
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.